Objective: To prevent invasive fungal disease (IFD) in acute myeloid leukemia (AML) patients, the use of posaconazole as a prophylactic antifungal agent has become standard in patients undergoing induction chemotherapy. However, there are few data comparing itraconazole and posaconazole as prophylactic antifungal agents in the real world. Methods: Patients at the Soonchunhyang University Seoul Hospital, who were treated with itraconazole or posaconazole for preventing IFD during induction chemotherapy for AML from January 2009 to April 2018, were included in the study. The collected clinical data were reviewed, and IFD was diagnosed using the revised definition of IFD from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. Results: A total of 53 patients were recruited to receive either posaconazole (n= 29) or itraconazole (n= 24). IFD occurred in seven patients (29.1%) who used posaconazole and in six patients (20.6%) who used itraconazole for antifungal prophylaxis (P= 0.475). The 100-day mortality rate was 4 (13.8%) in the posaconazole group and 2 (8.3%) in the itraconazole group (P= 0.535).
INTRODUCTION
Acute myeloid leukemia (AML) patients who are undergoing induction chemotherapy are at an increased risk of invasive fungal disease (IFD) because of prolonged neutropenia. IFDs are known to be associated with mortality, and difficult to detect early [1] . To prevent IFDs in AML patients, the use of prophylactic antifungal agents has become standard in that undergoing induction chemotherapy [2] . In recent years, studies have been conducted with various antifungal agents, such as fluconazole, itraconazole, posaconazole, voriconazole, isavuconazole, and micafungin [3] [4] [5] [6] [7] [8] [9] . Among these prophylactic fungal agents, the superiority of posaconazole was demonstrated by Cornely et al. [3] in 2007. Additionally, it is now standard to use posaconazole as a prophylactic antifungal agent in induction chemotherapy for AML. However, some retrospective studies have reported that posaconazole has no significantly different effect on breakthrough IFD and 100-day mortality compared to other drugs [10, 11] . This study aimed to compare the efficacy of posaconazole and itraconazole in the prevention of IFD in patients receiving first induction chemotherapy in a realworld setting.
MATERIALS AND METHODS

Study design
This retrospective, single-center study was carried out at Soonc- EORTC/MSG as "proven," "probable," or "possible" [1] . The date of IFD diagnosis was that on which radiographic evidence or a positive culture of a sterile sample was first noted. Neutropenia was defined as an absolute neutrophil count of < 500 cells/μL for 3 consecutive days.
Outcomes
All patients were carefully monitored for any evidence of IFDs at the beginning and end of the prophylaxis. The primary outcome was the incidence rate of breakthrough IFDs in the posaconazole and itraconazole groups. Secondary outcomes included the 100-day mortality rate, discontinuation of antifungal agents, and the profile of the breakthrough IFDs. Reasons for stopping antifungal prophylaxis were also analyzed.
Statistical analysis Comparisons between categorical variables was performed by
Fisher's exact test or the chi-square test; for continuous variables, the Mann-Whitney U-test was used. The survival distribution function was estimated using the Kaplan-Meier product-limit method. P < 0.05 indicated statistically significant differences.
RESULTS
Baseline characteristics
Between January 2009 and April 2018, a total of 102 patient data were recorded ( Fig. 1 ), 38 of whom did not use prophylactic anti- . There was no significant difference between the two groups in terms of median age, duration of neutropenia, and cytotoxic regimens ( Table 1 ).
Incidence of invasive fungal disease
During the treatment phase, IFD occurred in 6 (20.6%) patients who were using posaconazole and in 7 (29.1%) who were using itraconazole for antifungal prophylaxis (P = 0.475) ( Table 2 ). In six patients who had an invasive fungal infection after using posaconazole, one IFD was "proven," one was "probable" and four were "possible."
In seven patients who had an invasive fungal infection after using itraconazole, four IFDs were "probable" and three were "possible." 
Profile of breakthrough invasive fungal diseases
Breakthrough IFDs complicated 13 cases during induction chemotherapy ( is classically recommended. Itraconazole is effective for Candida, Cryptococcus, Aspergillus, and dimorphic fungi [4] , while posaconazole is effective for Candida, Aspergillus, Cryptococcus, Fusarium spp. and Zygomycetes [12] .
Most of the previous comparative studies on efficacy showed fa- [14] . Adversely, overall mortality was higher in the posaconazole group than in the itraconazole group. In the posaconazole group four patients died within 100 days, of whom only two had associated invasive fungal infection. In the itraconazole group, there were two deaths within 100 days, and both patients had an invasive fungal infection. A previous study comparing a posaconazole group against a fluconazole group showed no difference in the overall survival [10] . Comparing the posaconazole group and itraconazole group showed no significant difference in 100-day mortality; however, mortality due to IFD, an important cause of death, was lower in the posaconazole group than in the itraconazole group. The increase in mortality in the posaconazole group can be explained by the increase in the prevalence of AML in the elderly [15] . The baseline characteristics of our study population were similar in both groups; however, the median age of the posaconazole group was 6 years more than that of the itraconazole group. Although this difference was not statistically significant, it seems to have affected 100-day mortality [16] .
Excluding those who withdrew owing to persistent neutropenic fever, the rate of stopping medication was higher in the itraconazole group than in the posaconazole group. Posaconazole was discontinued when oral mucositis was severe. Itraconazole in syrup form was easy to take, even when oral mucositis was present. However, there were two cases of withdrawal due to poor tolerance of the itraconazole syrup preparation. To overcome the drawbacks of itraconazole syrup, itraconazole capsules could be administered instead; however, these present a problem in maintaining therapeutic drug monitoring, so it is better to use the syrup if possible [17] .
Nosocomial fungal infections generally increase the occurrence of Candida infections and decrease Aspergillus infections [18] . analysis showed that only cytogenetic risk of AML affected fungal infection (hazard ratio, 2.497; 95% confidence interval, 1.040-5.997; P = 0.041). As the rate of complete remission was low among those with higher AML risk stratification, the duration of neutropenia was prolonged, and this influenced the occurrence of breakthrough invasive fungal infections [15] .
In conclusion, there was no significant difference in the incidence of IFD and 100-day mortality between the patients with induction chemotherapy for newly diagnosed AML who received posaconazole and itraconazole as prophylactic antifungal agents. These results suggest that it would be worthwhile to ascertain whether posaconazole which is widely known as a better approach than itraconazole as prophylactic antifungal agents in real-world.
